Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
AN2 Therapeutics Inc.
ANTXUS
$
0.01
0.13%
After Hours
$
7.54
After Hours Volume:
608
| Close | Chg | Chg % |
|---|---|---|
| $7.53 | 1.12 | 17.47% |
Volume: 53.21K
65 Day Avg: 36.3K
6.27
Day Range
7.68
4.87
52 Week Range
22.49
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
ANTX Overview
Key Data
- Open $6.44
- Day Range 6.27 - 7.68
- 52 Week Range 4.87 - 22.49
- Market Cap $124.52M
- Shares Outstanding 19.43M
- Public Float 11.64M
- Beta 1.03
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$2.51
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 333.87K 05/31/23
- % of Float Shorted 2.87%
- Average Volume 36.3K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 4
Full Ratings
AN2 Therapeutics, Inc. (ANTX) Receives a Buy from SVB Securities
on TipRanks.com
An Insider Just Bought Shares of AN2 Therapeutics Inc; Could This Stock Be a Value Opportunity?
An Insider Just Bought Shares of AN2 Therapeutics Inc; Could This Stock Be a Value Opportunity?
on GuruFocus.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
on Benzinga.com
AN2 Therapeutics Insider Trades Send a Signal
on Benzinga.com
Top 5 Health Care Stocks That May Dip
on Benzinga.com
Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZN – Research Report), Halozyme (HALO – Research Report) and AN2 Therapeutics, Inc. (ANTX – Research Report) with...
on TipRanks.com
Uber, Lyft, AZZ And Other Big Losers From Tuesday
on Benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
on Benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
on Benzinga.com
Nasdaq Drops 200 Points; American Woodmark Shares Spike Higher
on Benzinga.com
SVB Securities Reaffirms Their Buy Rating on AN2 Therapeutics, Inc. (ANTX)
SVB Securities analyst Joseph Schwartz reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX - Research Report) on August 12 and set a price target of $27.00. The company's shares closed yesterday at $22.29.Schwartz cove...
on TipRanks.com
How Is The Market Feeling About AN2 Therapeutics?
on Benzinga.com
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.